Cellyan Biotechnology Co., Ltd (HKPD) Form 6-K — Oct 21, 2026
Cellyan Biotechnology (Nasdaq: HKPD) announced a 1-for-20 reverse stock split of its Class A and Class B ordinary shares, effective at the market open on October 26, 2026. Every twenty outstanding shares will consolidate into one, with par value increasing from $0.001 to $0.02 per share, a new CUSIP (G6365B112), and fractional shares rounded up at the participant level. Shareholder percentage interests are otherwise unchanged. The company said the split is primarily intended to regain compliance with Nasdaq's minimum bid price requirement, but cautioned there is no assurance of regaining or maintaining compliance.
Key figures
- New cusip
- G6365B112
- Effective date
- 2026-10-26
- Par value after
- $0.02 per share
- Par value before
- $0.001 per share
- Reverse split ratio
- 1:20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.